Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | AGXT | P21549 | 3/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 2/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31643222 | 0.87 | PREP (0.49) | PREPCA12CA1CA9IDO1 | |
| SCHEMBL6156659 | 0.85 | IDO1 (0.55) | PREPIDO1AGXT | |
| SCHEMBL12201060 | 0.85 | PREP (0.59) | PREPCA12CA1CA9IDO1 | |
| SCHEMBL481257 | 0.83 | IDO1 (0.50) | IDO1APPMAPTHPGDDUT | |
| SCHEMBL2981195 | 0.83 | TRPA1 (0.33) | PREPIDO1AGXTBACE1DUT | |
| SCHEMBL7301986 | 0.82 | PREP (0.46) | PREPCA12CA1CA9IDO1 | |
| SCHEMBL6763899 | 0.82 | PREP (0.53) | PREPCA12CA1CA9 | |
| SCHEMBL15489965 | 0.81 | TDP1 (0.37) | AGXTBACE1DUTRXRARXRB | |
| SCHEMBL12426281 | 0.81 | PREP (0.46) | PREPCA12CA1CA9MAPT | |
| SCHEMBL12855670 | 0.81 | AGXT (0.52) | CA1CA9IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553842-B2 | Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases | ARRAY BIOPHARMA INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1838316-A2 | MACROCYCLIC ANALOGS FOR THE TREATMENT OF IMMUNOREGULATORY DISORDERS AND RESPIRATORY DISEASES | Array Biopharma, Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006078724-A2 | MACROCYCLIC ANALOGS FOR THE TREATMENT OF IMMUNOREGULATORY DISORDERS AND RESPIRATORY DISEASES | ARRAY BIOPHARMA NC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160838-A1 | Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases | ARRAY BIOPHARMA INC. | 2006-07-20 | — | — | US | disclosed |
| EP-0594588-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1994-05-04 | — | — | EP | disclosed |
| WO-1991013054-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | PFIZER LIMITED (GB) | 1991-09-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160838-A1 | Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases | TSLP, XDH, IFNG | PREP 1173/4885CA12 2098/4885CA1 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.